TABLE I.

Basel ine clinical characteristics in the study

	Patient demographics and clinical characteristics	n (%)	Median (IQR)
Demographic
Sex	Female	39 (41.5)
	Male	55 (58.5)
Age (y)			49.5 (41.8–60)
Comorbidity
AERD	No AERD	73 (77.7)
	AERD	21 (22.3)
Asthma	No or prior diagnosis	39 (41.5)
	Active	55 (58.5)
Allergic rhinitis	Absence	39 (41.5)
	Presence	55 (58.5)
Prior ESS	Primary	50 (53.2)
	Revision	44 (46.8)
Steroid use	No	41 (43.6)
	Nasal and/or inhaled only	25 (26.6)
	Oral steroid with or without nasal/inhaled	28 (29.8)
Smoking	Never smoker	72 (76.6)
	Current or prior smoker	22 (23.4)
Intraoperative findings
Pus	Absence	76 (80.9)
	Presence	18 (19.1)
Allergic mucin	Absence	66 (70.2)
	Presence	28 (29.8)
PROMs
SNOT-22	Pre-ESS		22.5 (0–46.0)
	Post-ESS		19.0 (7.8–40.1)
CRS-PRO	Pre-ESS		NA
	Post-ESS		15.0 (6.0–26.3)
Radiographic score
MLM	Pre-ESS		28 (20.0–36.0)
	Post-ESS		7.5 (3.0–20.0)
Endoscopic score
MLK	Pre-ESS		NA
	Post-ESS		2 (0–6.0)
PR		37 (39.4)
TPS in PR			2.0 (1.0–3.0)
Tissue biomarkers (pg/mg)
IL-4			7.3 (3.0–14.1)
IL-5			4.0 (1.1–10.0)
IL-6			7.6 (2.9–21.9)
IL-13			10.6 (3.3–22.9)
IL-10			1.0 (0.6–2.7)
IL-21			1.3 (0.5–2.6)
ITAC			29.8 (15.4–51.0)
TNF-α			0.9 (0.4–2.5)
GM-CSF			0.4 (0.2–3.1)
Fractalkine			5S0.0 (233.1–1246)
IFN-γ			0.7 (0.3–3.7)
MIP-1α			17.9 (10.0–42.6)
MIP-1β			35.4 (18.8–72.0)
MIP-3α			5.3 (2.3–14.3)
IL-1β			0.5 (0.2–1.2)
Anti-dsDNA IgG (IU/mg)			337.0 (158.0–712.1)
ECP (ng/mg)			924.5 (395.3–2375)

Demographics, inflammatory mediators, clinical variables, and PROMs measured in the study (N = 94).

AERD, Aspirin exacerbated respiratory disease; IQR, interquartile range; NA, not available.